Last reviewed · How we verify
CD30-positive peripheral T-cell lymphoma
Approved treatments
- Brentuximab · University of Arizona
- Adcetris · Pfizer
Adcetris works by binding to cancer cells that express CD30 and delivering a toxic payload to kill the cells.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- CD30-positive peripheral T-cell lymphoma patent landscape — cliff calendar, originator estates, attackable patents
- CD30-positive peripheral T-cell lymphoma treatment landscape brief
- CD30-positive peripheral T-cell lymphoma treatment updates RSS
Frequently asked questions about CD30-positive peripheral T-cell lymphoma
What drugs treat CD30-positive peripheral T-cell lymphoma?
Tracked treatments include Brentuximab, Adcetris.
What is the treatment for CD30-positive peripheral T-cell lymphoma?
Standard treatment for CD30-positive peripheral T-cell lymphoma includes Brentuximab, Adcetris. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: CD30-positive peripheral T-cell lymphoma patent cliff · CD30-positive peripheral T-cell lymphoma CI report
- Treatment: Brentuximab · University of Arizona
- Treatment: Adcetris · Pfizer
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing